Seqirus gets FDA nod for Fluad

Adults 65 years old and older have a new vaccine to protect against seasonal influenza. The Food and Drug Administration has given the green light to Seqirus for the first adjuvanted quadrivalent influenza vaccine, Fluad Quadrivalent (Influenza Vaccine, Adjuvanted), to help protect adults 65 years and older against seasonal influenza.

"Adults 65 years and older are at high risk for influenza-related complications each season and it is important to have influenza vaccines to help protect this vulnerable population," said Anjana Narain, Seqirus executive vice president and general manager. "As part of our leading role on the front line of influenza prevention, we are pleased to offer Fluad Quadrivalent, another seasonal vaccine option for healthcare providers and their patients in the fight against influenza."

"The burden of seasonal influenza among adults 65 and older, remains an important public health concern," said Gregg Sylvester, chief medical officer at Seqirus."At Seqirus, we're committed to developing advanced technologies and vaccines designed to address unmet needs, especially in vulnerable populations, such as adults 65 years and older."